The findings of this study suggest that approximately 1 in 7 patients diagnosed with MBC will require radiotherapy for BRM; this proportion is even higher among patients with ERBB2-positive and triple-negative MBC, potentially justifying screening for intracranial metastatic disease in these patient populations. The gene discussed is ERBB2; the disease is metastatic neoplasm.